A Phase 3 interventional study of Raphamin and Placebo in Coronavirus Disease 2019 (COVID-19), sponsored by Materia Medica Holding. Completed at 36 sites in Russia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-06.
Sponsored by Materia Medica Holding · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in COVID-19 with a site in Russia — 1 open to participants now, 2 under way, none of them phase 3. COVID-19 · Russia.
Among the 16 studies in COVID-19 with a site in Russia, this one is one of 2 that started in 2022, is the only one in phase 3, and was the 10th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →1 of the 16 studies in COVID-19 with a site in Russia is open now. Recruiting first, the newest first:
Tomsk National Research Medical Center of the Russian Academy of Sciences · Sites in Russia
Ages 18+ · Healthy volunteers
A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 4
First in 2020; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 771 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 200 across the 9 interventional studies, 2,000 across the 7 observational. Of the 13 that completed or were terminated, 4 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 16 have an industry lead sponsor. The 10 most frequent:
Materia Medica Holding is the lead sponsor of 43 studies on the registry; 4 are open to participants now.
Materia Medica Holding has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
1 of the studies in COVID-19 with a site in Russia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06803862National Medical Research Center for Therapy and Preventive MedicineRegiStry Of the multiFaceted medIcal cenTer | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in COVID-19 with a site in Russia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Multicenter double-blind placebo-controlled parallel-group randomized clinical trial of efficacy and safety of Raphamin in the treatment of coronavirus disease 2019 in outpatients.
Design: multicenter, double blind, placebo-controlled, parallel group randomized clinical trial.
The study enrolls outpatients of either gender aged 18-75 years with increased body temperature > 37.5°C and other upper respiratory infection symptoms (cough, chest congestion, sore throat, nasal congestion/moderate rhinorrhea). The investigator should specify the patient's status of vaccination for COVID-19, influenza and other infections. Patients within the first four weeks after any vaccination/booster vaccination are not considered as candidates to participate in the study.
Nasopharyngeal swabs and rapid COVID-19 test are made after signing informed consent (two versions are used: 1) for patients consented for laboratory tests; 2) for patients without the consent).
Patients with a positive rapid test and presence of mild COVID-19 (upper respiratory infection symptoms, no symptoms of moderate or severe forms) within 24 hours after manifestation of the first disease symptoms are considered as candidates for the study. Oxygen saturation (SpO2) is measured by pulse oximetry in all patients (pulse oximeters are provided by the study sponsor). If SpO2 is ≥95%, a patient may be selected for the study. Baseline severity for COVID-19 symptoms is evaluated using the scoring system "Assessment of 14 Common COVID-19-Related Symptoms" (FDA, 2020). This scoring system assesses the follows symptoms:
Each symptom is scored individually using the following scoring values:
The minimal baseline score for COVID-19-related symptoms is defined as follows: at least two symptoms with a score of 2 or higher, with the exception of taste and smell where subjects may have a score of 1 or higher, and the absence of shortness of breath (difficulty breathing).
If more severe symptoms are presented, the patient is not included in the study. The therapeutic approach is determined by the current edition of the clinical recommendations of the Ministry of Health of the Russian Federation "Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)".
At visit 1 (Day 1), in addition to rapid COVID-19 test and SpO2 measurement, the investigator will collect complaints and medical history of the patient, perform objective examination including vital signs (blood pressure, heart rate and respiration rate), record concomitant diseases and concomitant therapy, perform nasopharyngeal smearing for further PCR for SARS-CoV-2, laboratory tests will be made (if the patient gave his/her consent for blood and urine sampling).
Patients who meet all the inclusion criteria and do not have exclusion criteria at Visit 1 (Day 1) are randomized into one of two groups: patients in group 1 receive Raphamin for 5 days; patients in group 2 receive placebo according to the Raphamin regimen.
If positive PCR test is received (confirmation of new coronavirus disease COVID-19), the patient continues to participate in the study. If PCR result is negative, the patient completes participation in the study ahead of schedule, and his further therapy is determined by the investigator in accordance with the standard of care.
Electronic patient diary (EPD) is utilized in the study where morning and evening axillary temperature records are made with the time of measurement. The sponsor provides a classical mercury-free thermometer to each patient. In addition, presence and severity of the disease symptoms according to the scoring system "Assessment of 14 Common COVID-19-Related Symptoms", antipyretics administration and probable worsening of disease duration should also be recorded in EPD. All patients are provided with paracetamol. The physician instructs the patient how to fill in the diary. The EPD is available for filling in within 28 days of participation in the study.
Overall, patients are observed for 28 days (screening and randomization up to 1 day, treatment for 5 days, follow-up till 28th day).
During the study, six visits are planned: on days 1, 3, 6, 10, 21, and 28 (visits 1, 2, 3, 4, 5, and 6). Visits 1, 3, and 4 are in person (visits to the patient or visits to the medical center) when the physician examines the patient and monitors EPD records. At visit 3, the patient's adherence to treatment is assessed and laboratory tests are performed. Visits 2, 5 and 6 are phone surveys to determine the patient's condition, presence/absence of complaints. In case of worsening of disease duration, the physician makes an extra visit. Patients with COVID-19 progression to more severe form as well as hospitalized patients are considered as reaching the study endpoints and terminate participation in the study ahead of schedule. The therapeutic approach is determined by the current edition of the clinical recommendations of the Ministry of Health of the Russian Federation "Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)".
During the study, the use of paracetamol and medicines for the treatment of concomitant diseases is allowed, with the exception of the drugs specified in the section "Prohibited concomitant treatment".
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tablet for oral use.
Drug: Raphamin
Tablet for oral use.
Drug: Placebo
Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. On the first day, 8 tablets should be administered using the following regimen: 1 tablet every 30 minutes in the first 2 hours (5 tablets in total within 2 hours), then additionally one tablet 3 times with regular time intervals. From day 2 onwards, 1 tablet taken 3 times daily. The treatment period is 5 days.
Also known as: MMH-407
Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. Placebo is administered according to the Raphamin regimen.
Number of Participants With COVID-19 Progression to a More Severe Form
Severity of COVID-19 is assessed in accordance with criteria presented in the current edition of the clinical recommendations of the Ministry of Health of the Russian Federation "Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)".
Time frame: 28 days
Time to Sustained Clinical Recovery After New Coronavirus Disease COVID-19.
Sustained clinical recovery is a sustained improvement of clinical symptoms for at least 4 consecutive days. The day of improvement is considered the first of these 4 days. Criteria for improvement of clinical symptoms (according to the scoring system "Assessment of 14 Common COVID-19-Related Symptoms") are defined as follows: * a score of 1 or 0 (for stuffy or runny nose, sore throat, low energy or tiredness, muscle or body aches, headache, chills or shivering, feeling hot or feverish, nausea, diarrhea); * a score 0 (for shortness of breath/difficulty breathing and vomiting); * a score no more than 2 (for cough); * no new symptoms with a score of 1 or 0; * axillary temperature ≤37.3°С.
Time frame: 28 days
Percentage of Hospitalized Patients
Based on the medical records.
Time frame: 28 days
Time to COVID-19 Progression to a More Severe Form
Severity of COVID-19 will be assessed in accordance with the criteria presented in the current edition of the clinical recommendations of the Ministry of Health of the Russian Federation "Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)".
Time frame: 28 days
Percentage of Patients With Negative PCR Test for SARS-CoV-2
Number of patients with a negative PCR test result for SARS-CoV-2 on days 6 and 10 of observation. Based on the medical records.
Time frame: On days 6 and 10
Number of Participants With Adverse Events (AEs)
The presence of adverse events. Based on medical records.
Time frame: From day 1 to day 6
Severity of AEs
The intensity (severity) of adverse events. Based on medical records.
Time frame: From day 1 to day 6
Causal Relationship of AEs to the Sudy Drug
The causal relationship to the study drug of adverse events. Based on medical records.
Time frame: From day 1 to day 6
Outcome of AEs
The outcome of adverse events. Based on medical records.
Time frame: From day 1 to day 6
Changes in Vital Signs: Pulse Rate/Heart Rate in Beats Per Minute (Bpm)
The outcome measure is based on the medical records. The patient's heart rate (heart rate) is measured by the physician in visits 1, 3 and 4 (on days 1 and 6).
Time frame: On Visit 1 (day 1), Visit 3 (day 6), Visit 4 (day10)
Changes in Vital Signs: Respiration Rate/Breathing Rate in Breaths Per Minute
Outcome Measure is based on the medical records. The patient's respiration rate (breathing rate) is measured by physician in visits 1, 3 and 4 (on days 1 and 6).
Time frame: On Visit 1 (day 1), Visit 3 (day 6), Visit 4 (day10)
Changes in Vital Signs: Capillary Blood Oxygen Saturation (SpO2)
Outcome Measure is based on the medical records. The patient's capillary blood oxygen saturation (SpO2) is measured by physician in visits 1, 3 and 4 (on days 1 and 6).
Time frame: On Visit 1 (day 1), Visit 3 (day 6), Visit 4 (day10)
Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg)
Outcome Measure is based on the medical records. The patient's blood pressure is measured by the physician in visits 1, 3 and 4 (on days 1 and 6).
Time frame: On Visit 1 (day 1), Visit 3 (day 6), Visit 4 (day10)
Percentage of Patients With Clinically Significant Abnormal Laboratory Tests
Measure is based on the Hematology, blood chemistry, and urinalysis parameters, which are beyond the reference values at the end of treatment.
Time frame: On Visit 1 (day 1) and Visit 3 (day 6)
| Milestone | Raphamin | Placebo |
|---|---|---|
| Started | 382 | 389 |
| Completed | 356 | 358 |
| Not completed | 26 | 31 |
| Withdrew: Negative pcr result for sars-cov-2 | 20 | 26 |
| Withdrew: Patient's inability or refusal to comply with protocol requirements | 3 | 1 |
| Withdrew: Need to prescribe prohibited drugs in this study | 1 | 3 |
| Withdrew: Patient's desire to complete the study early due to treatment failure or any other reason | 2 | 0 |
| Withdrew: Deviation from the schedule of face-to-face visits on more than 1 day | 0 | 1 |
Severity of COVID-19 is assessed in accordance with criteria presented in the current edition of the clinical recommendations of the Ministry of Health of the Russian Federation "Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)".
| Participants | Raphamin | Placebo |
|---|---|---|
| Number of Participants With COVID-19 Progression to a More Severe Form | 59 | 89 |
Sustained clinical recovery is a sustained improvement of clinical symptoms for at least 4 consecutive days. The day of improvement is considered the first of these 4 days. Criteria for improvement of clinical symptoms (according to the scoring system "Assessment of 14 Common COVID-19-Related Symptoms") are defined as follows: * a score of 1 or 0 (for stuffy or runny nose, sore throat, low energy or tiredness, muscle or body aches, headache, chills or shivering, feeling hot or feverish, nausea, diarrhea); * a score 0 (for shortness of breath/difficulty breathing and vomiting); * a score no more than 2 (for cough); * no new symptoms with a score of 1 or 0; * axillary temperature ≤37.3°С.
| day | Raphamin | Placebo |
|---|---|---|
| Time to Sustained Clinical Recovery After New Coronavirus Disease COVID-19. | 4.5 ± 2.4 | 5.8 ± 4.7 |
Based on the medical records.
| Participants | Raphamin | Placebo |
|---|---|---|
| Percentage of Hospitalized Patients | 0 | 0 |
Severity of COVID-19 will be assessed in accordance with the criteria presented in the current edition of the clinical recommendations of the Ministry of Health of the Russian Federation "Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)".
| day | Raphamin | Placebo |
|---|---|---|
| Time to COVID-19 Progression to a More Severe Form | 1.6 ± 0.8 | 2.4 ± 3.9 |
Number of patients with a negative PCR test result for SARS-CoV-2 on days 6 and 10 of observation. Based on the medical records.
| Participants | Raphamin | Placebo |
|---|---|---|
| Day 6 | 68 | 66 |
| Day 10 | 93 | 89 |
The presence of adverse events. Based on medical records.
| Participants | Raphamin | Placebo |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 29 | 46 |
The intensity (severity) of adverse events. Based on medical records.
| Number of AE | Raphamin | Placebo |
|---|---|---|
| Mild | 25 | 43 |
| Moderate | 14 | 18 |
| Severe | 2 | 0 |
The causal relationship to the study drug of adverse events. Based on medical records.
| Number of AEs | Raphamin | Placebo |
|---|---|---|
| No relation | 39 | 52 |
| Probable | 1 | 0 |
| Possible | 1 | 2 |
| Doubtful | 0 | 6 |
| Certain | 0 | 1 |
The outcome of adverse events. Based on medical records.
| Number of AEs | Raphamin | Placebo |
|---|---|---|
| Recovery/resolution | 23 | 40 |
| Incomplete recovery/ resolution | 5 | 6 |
| No recovery/resolution | 1 | 0 |
| Unknown | 12 | 15 |
The outcome measure is based on the medical records. The patient's heart rate (heart rate) is measured by the physician in visits 1, 3 and 4 (on days 1 and 6).
| Bpm | Raphamin | Placebo |
|---|---|---|
| Visit 1 | 81.7 ± 10.4 | 81.9 ± 10.5 |
| Visit 3 | 73.9 ± 6.3 | 74.4 ± 6.4 |
| Visit 4 | 72.6 ± 6.0 | 73.2 ± 5.8 |
Outcome Measure is based on the medical records. The patient's respiration rate (breathing rate) is measured by physician in visits 1, 3 and 4 (on days 1 and 6).
| Breaths per minute | Raphamin | Placebo |
|---|---|---|
| Visit 1 | 17.1 ± 1.4 | 17.2 ± 1.5 |
| Visit 3 | 16.6 ± 1.2 | 16.5 ± 1.4 |
| Visit 4 | 16.4 ± 1.3 | 16.4 ± 1.3 |
Outcome Measure is based on the medical records. The patient's capillary blood oxygen saturation (SpO2) is measured by physician in visits 1, 3 and 4 (on days 1 and 6).
| percentage of oxygen | Raphamin | Placebo |
|---|---|---|
| Visit 1 | 97.8 ± 0.9 | 97.8 ± 0.8 |
| Visit 3 | 98.3 ± 0.8 | 98.3 ± 0.8 |
| Visit 4 | 98.4 ± 0.8 | 98.5 ± 0.8 |
Outcome Measure is based on the medical records. The patient's blood pressure is measured by the physician in visits 1, 3 and 4 (on days 1 and 6).
| mmHg | Raphamin | Placebo |
|---|---|---|
| SBP/Visit 1 | 122.1 ± 9.5 | 122.1 ± 9.9 |
| SBP/Visit 3 | 121.8 ± 8.3 | 121.2 ± 8.2 |
| SBP/Visit 4 | 121.1 ± 7.6 | 121.2 ± 7.9 |
| DBP/Visit 1 | 76.9 ± 6.8 | 76.8 ± 7.4 |
| DBP/Visit 3 | 76.5 ± 6.2 | 76.3 ± 6.2 |
| DBP/Visit 4 | 76.2 ± 6.0 | 76.1 ± 6.3 |
Measure is based on the Hematology, blood chemistry, and urinalysis parameters, which are beyond the reference values at the end of treatment.
| Participants | Raphamin | Placebo |
|---|---|---|
| Percentage of Patients With Clinically Significant Abnormal Laboratory Tests | 13 | 16 |
Collected over Registration of AEs begins after the first dose of study drug and continues throughout the entire period of study therapy - 28 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Raphamin | 0/382 (0%) | 1/382 (0.3%) | 29/382 (7.6%) |
| Placebo | 0/389 (0%) | 0/389 (0%) | 46/389 (11.8%) |
| Event | Raphamin | Placebo |
|---|---|---|
| Worsening of atrial fibrillationCardiac disorders | 1/382 | 0/389 |
| Complicated fractureInjury, poisoning and procedural complications | 1/382 | 0/389 |
| Event | Raphamin | Placebo |
|---|---|---|
| Increased C-reactive proteinInvestigations | 0/382 | 3/389 |
| Increased transaminasesInvestigations | 1/382 | 3/389 |
| HeadacheNervous system disorders | 0/382 | 3/389 |
| Abdominal painGastrointestinal disorders | 2/382 | 0/389 |
| Itching, cutaneousSkin and subcutaneous tissue disorders | 2/382 | 1/389 |
| ToothacheGastrointestinal disorders | 0/382 | 2/389 |
| NauseaGastrointestinal disorders | 1/382 | 2/389 |
| Increased blood pressureInvestigations | 1/382 | 2/389 |
| Increased total bilirubinInvestigations | 0/382 | 2/389 |
| Abdominal distensionGastrointestinal disorders | 1/382 | 0/389 |
| Age, Categorical(Participants) | Raphamin | Placebo | Total |
|---|---|---|---|
| <=18 years | 3 | 2 | 5 |
| Between 18 and 65 years | 336 | 352 | 688 |
| >=65 years | 43 | 35 | 78 |
| Age, Continuous(years) | Raphamin | Placebo | Total |
|---|---|---|---|
| Mean | 43.3 ± 15.3 | 43.4 ± 14.3 | 43.4 ± 14.8 |
| Sex: Female, Male(Participants) | Raphamin | Placebo | Total |
|---|---|---|---|
| Female | 233 | 249 | 482 |
| Male | 149 | 140 | 289 |
| Race and Ethnicity Not Collected(Participants) | Raphamin | Placebo | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Raphamin | Placebo | Total |
|---|---|---|---|
| Russia | 382 | 389 | 771 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2022 to primary completion in Aug 2023, 15 months.
Results were first posted in Jan 2025, 1 year 4 months after primary completion.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 15 months is above that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MMH-407